

Thermo Fisher and Arsenal Biosciences to support clinical manufacturing of autologous T-cell therapies

29 March 2023 | News

As ArsenalBio pioneers a new approach to treat solid tumours using engineered T-cell therapies

American firms Thermo Fisher Scientific and Arsenal Biosciences, Inc. have announced an update to their strategic collaboration to further the development of manufacturing processes for new cancer treatments.

This research and process development-focused collaboration has enabled ArsenalBio to develop a robust manufacturing process for their next-generation, programmable autologous T cells for the treatment of cancer.

ArsenalBio recently advanced its lead product candidate into clinical manufacturing of its autologous integrated circuit T cell (ICT) therapy for platinum-resistant ovarian cancer. ArsenalBio's work to develop multi-functional CAR-T cell therapies is enabled by Thermo Fisher's Cell Therapy Systems (CTS) portfolio of products, including the Gibco[™] CTS[™] Xenon[™] Electroporation System and the Gibco[™] CTS[™] Rotea[™] Counterflow Centrifugation System.

Thermo Fisher began its collaboration with ArsenalBio in 2020 to help ArsenalBio overcome challenges associated with cell therapy manufacturing by working together to support development of a clinical-scale gene editing process. In addition, ArsenalBio received early access to Thermo Fisher's latest instrumentation and reagents.